Added to YB: 2026-09-15
Pitch date: 2026-09-12
SCYX [neutral]
SCYNEXIS, Inc.
-4.96%
current return
Author Info
No bio for this author
Company Info
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.
Market Cap
$48.2M
Pitch Price
$4.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.18
P/E
-3.64
EV/Sales
-0.21
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage Day 4 Session 4 - SCYNEXIS, Inc.
SCYX (quick overview): SCYNEXIS at $4.84 is a high-risk rare-disease re-rating opportunity built around SCY-770, a clinically advanced AMPK activator acquired for $8M upfront. A Phase 1 PK study should finish this quarter, followed by a Phase 2 ADPKD trial in 4Q, with management targeting a potential efficacy update in next year’s second half. The multi-pathway rationale is attractive, but human efficacy in ADPKD remains unproven and M&A potential is speculative.
Read full article (2 min)